Bovilis IBR marker Live

Pooblaščeno

- Infectious Bovine rhinotracheitis virus, strain GK/D gE gene-deleted, Inactivated

Product identification

Ime zdravila:
Bovilis IBR marker Live
Bovilis IBR Marker live

Učinkovina:
Na voljo samo v English

Ciljne živalske vrste:
govedo

Pot uporabe:
Nazalna uporaba
intramuskularna uporaba

Product details

Učinkovina / Jakost:
Na voljo samo v English
7.30 unit(s) / 1.00 Dose

Farmacevtska oblika:
Liofilizat za suspenzijo za injiciranje

Withdrawal period by route of administration:

Nazalna uporaba:

- **govedo**

  - Milk. 0 day

  - Meat and offal. 0 day

intramuskularna uporaba:

- **govedo**

  - Milk. 0 day

  - Meat and offal. 0 day

Anatomsko-terapevtsko-kemična veterinarska oznaka (ATCvet):

QI02AD01

Pravni status za dobavo / izdajo zdravila:

Zdravilo, ki se izdaja na veterinarski recept

Status dovoljenja:

Valid

Authorised in:

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

---

Opis ovojnine:

Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English
Na voljo samo v English

Additional information

Entitlement type:
Na voljo samo v English French Croatian Italian Latvian Finnish Swedish Icelandic Norwegian

Pravna podlaga za izdajo dovoljenja za promet z zdravilom:
Na voljo samo v English French Italian Latvian Norwegian

Imetnik dovoljenja za promet z zdravilom:
Intervet Deutschland GmbH

Marketing authorisation date:
2/02/2012

Proizvodna mesta, odgovorna za sproščanje serij:
INTERVET INTERNATIONAL B.V.

Pristojni organ:
Paul Ehrlich Institute

Številka dovoljenja :
PEI.V.11616.01.1

Datum spremembe statusa dovoljenja:
2/02/2012

Referenčna država članica:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Številka postopka:
NL/V/0105/001

Zadevne države članice:

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Croatian Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Estonian English French Swedish Icelandic Norwegian

---

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Povzetek glavnih značilnosti zdravila

Ta dokument ne obstaja v tem jeziku (slovenščina). Spodaj ga najdete v drugem jeziku.
